G6PD Deficiency Clinical Trial
Official title:
Evaluation of a Diagnostic to Identify G6PD Deficiency in Brazil
Verified date | September 2021 |
Source | PATH |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Th objectives of this study are: - To determine the performance of G6PD tests in detecting G6PD activity and hemoglobin (Hb) compared to a reference assay - To assess the comprehension of the G6PD test packaging and labelling among intended users - To assess the usability of G6PD test result outputs among intended users
Status | Completed |
Enrollment | 1754 |
Est. completion date | December 31, 2019 |
Est. primary completion date | December 31, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 2 Years and older |
Eligibility | 1. Participants with unknown G6PD status Inclusion criteria: - Febrile patients seeking care at the Manaus or Porto Velho clinics - 2 years age or older - Willing to provide informed consent Exclusion criteria - Younger than 2 years of age - Participants who received a blood transfusion in the last 3 months, self report - Unwilling to provide informed consent 2. Participants with known G6PD status Inclusion criteria: - Included in previous G6PD surveys and provided consent to be contacted again - 2 years of age or older - Willing to provide informed consent or assent Exclusion criteria: - Younger than 2 years of age - Participants who received a blood transfusion in the last 3 months, self report - Unwilling to provide informed consent or assent or unavailable during study visit 3. Health workers Inclusion Criteria: - Provides malaria case management at study facility or study site - Considered an intended user of quantitative POC G6PD tests - Trained and proficient in the use of the POC G6PD test - Willing to provide informed consent Exclusion Criteria: - Does not provide malaria case management at study facility or study site - Not considered an intended user of quantitative POC G6PD tests - Not trained or not proficient in the use of the POC G6PD test - Unwilling to provide informed consent |
Country | Name | City | State |
---|---|---|---|
Brazil | Tropical Medicine Foundation Doctor Heitor Vieira Dourado | Manaus | Amazonas |
Brazil | Centro de Pesquisa em Medicina Tropical de Rondônia | Porto Velho | Rondônia |
Lead Sponsor | Collaborator |
---|---|
PATH | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sensitivity of SD Biosensor STANDARD G6PD Test for Identifying G6PD Deficient Individuals | For the purposes of this study, an individual was considered G6PD deficient if they tested positive in the Pointe Scientific assay. A true positive was defined as a participant with = 30% of normal G6PD activity in circulating venous blood determined by the Pointe Scientific test.
Diagnostic sensitivity of the SD Biosensor STANDARD G6PD test is defined as the percentage of participants who tested positive for G6PD deficiency on the reference test who were identified by the test assay as positive, calculated as: Number of participants who were both test and true positive / (Number of participants who were test and true positive + Number of participants who were test negative but true positive [ie false negative]) * 100%. Sensitivity of the SD Biosensor STANDARD G6PD test was calculated from both venous and capillary blood samples. |
All samples were collected on study day 1 | |
Primary | Sensitivity of SD Biosensor STANDARD G6PD Test for Identifying Women With Intermediate G6PD Activity | To investigate the performance of the SD Biosensor STANDARD G6PD test to distinguish females with intermediate G6PD activity from females with normal activity, assay sensitivity was determined at a G6PD activity threshold of 70%. A true positive for intermediate G6PD activity in females was defined as G6PD activity between 30 and 70% of normal in circulating venous blood as determined by the Pointe Scientific test.
Sensitivity of the SD Biosensor STANDARD G6PD test is the percentage of women who tested positive for intermediate G6PD activity on the reference test who were identified by the test assay as positive, calculated as: Number of women who were both test and true positive / (Number of women who were test and true positive + Number of women who were test negative but true positive [ie false negative]) * 100%. Sensitivity of the SD Biosensor STANDARD G6PD test for identifying females with intermediate G6PD activity was calculated from both venous and capillary blood samples. |
All samples were collected on study day 1 | |
Primary | Specificity of SD Biosensor STANDARD G6PD Test for Identifying G6PD Deficient Individuals | For the purposes of this study, an individual was considered G6PD deficient if they tested positive by the Pointe Scientific assay. A true negative was defined as > 30% of normal G6PD activity in circulating venous blood as determined by the Pointe Scientific test.
Specificity is the percentage of participants who tested negative for G6PD deficiency on the reference test who were identified as negative using the test assay, calculated as: Number of participants who were both test and true negative / (Number of participants who were test and true negative + Number of participants who were test positive but true negative [ie false positive]) * 100%. Specificity of the SD Biosensor STANDARD G6PD test was calculated from both venous and capillary blood samples. |
All samples were collected on study day 1 | |
Primary | Specificity of SD Biosensor STANDARD G6PD Test for Identifying Women With Intermediate G6PD Activity | To investigate the performance of the SD Biosensor STANDARD G6PD test to distinguish females with intermediate G6PD activity from females with normal activity, the specificity was determined at a G6PD activity threshold of 70%. A true negative for intermediate G6PD activity in females was defined as G6PD activity > 70% of normal in circulating venous blood as determined by the Pointe Scientific test.
Specificity is the percentage of participants who tested negative for G6PD deficiency on the reference test who were identified as negative using the test assay, calculated as: Number of participants who were both test and true negative / (Number of participants who were test and true negative + Number of participants who were test positive but true negative [ie false positive]) * 100%. Specificity of the SD Biosensor STANDARD G6PD test was calculated from both venous and capillary blood samples. |
All samples were collected on study day 1 | |
Secondary | Accuracy Between the SD Biosensor STANDARD G6PD Test Assay and the Pointe Scientific Test Kit | Accuracy between the SD Biosensor STANDARD G6PD test assay and the Pointe Scientific G6PD reference assay was calculated as the percent agreement between both G6PD tests, ie, the percentage of participants with the same diagnosis according to both tests (either deficient, intermediate, or normal G6PD levels).
Accuracy of the SD Biosensor STANDARD G6PD test was calculated from both venous and capillary blood samples. |
All samples were collected on study day 1 | |
Secondary | Accuracy Between the SD Biosensor STANDARD G6PD Test Measure of Hemoglobin and the Reference HemoCue Hemoglobin Test | Accuracy between the SD Biosensor STANDARD G6PD test measure of hemoglobin and the HemoCue hemoglobin reference assay was calculated as the percentage agreement between both tests, ie, the percentage of participants with the same diagnosis according to both tests (either non/mild anemia, moderate anemia or severe anemia). | All samples were collected on study day 1 | |
Secondary | Accuracy Between the SD Biosensor STANDARD G6PD Test Measure of Hemoglobin and the Hemoglobin Measured in a Complete Blood Count | Accuracy between the SD Biosensor STANDARD G6PD test measure of hemoglobin and the hemoglobin result from the complete blood count (CBC) reference assay (using an automated hematology analyzer) was calculated as the percentage agreement between both tests, ie, the percentage of participants with the same diagnosis according to both tests (either non/mild anemia, moderate anemia or severe anemia). Complete blood counts were only conducted for participants enrolled at the site in Manaus. | All samples were collected on study day 1 | |
Secondary | Median G6PD Values Measured by the SD Biosensor STANDARD G6PD Test for Venous and Capillary Blood Samples | All samples were collected on study day 1 | ||
Secondary | Number of Participants Who Met Acceptance Criteria for Label Comprehension | After completing training, health worker participants were asked to complete a questionnaire to assess their comprehension of the test label. The questionnaire consisted of 13 multiple-choice questions with mutually exclusive options and a single correct answer focused on aspects of the product label including key warnings, limitations, and restrictions as well as the proper test procedure.
Acceptance (success) criterion for label comprehension was defined as at least 85% correct responses (11 out of 13 possible points). |
Day 1 | |
Secondary | Number of Participants Who Met Acceptance Criteria for Accurate Results Interpretation | After completing training, health worker participants were asked to complete a questionnaire to assess their ability to interpret the test result outputs. The questionnaire consisted of seven short-answer questions (5 valid results, 2 invalid results) focused on the participant's ability to read the results screen, record the simulated G6PD and hemoglobin quantitative results, and classify the results as normal, intermediate, deficient, or invalid.
For each valid result, three points were possible: (one for G6PD result transcription, one for hemoglobin result transcription, and one for result interpretation) and for each invalid result, one point was possible, resulting in a total of 17 possible points. Acceptance (success) criterion for results interpretation was defined as at least 85% correct responses (15 out of 17 possible points). |
Day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05096702 -
Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil
|
||
Recruiting |
NCT04073953 -
Primaquine Enantiomers in G6PD Deficient Human Volunteers
|
Phase 1 | |
Completed |
NCT02434952 -
Safety and Tolerability of Low Dose Primaquine
|
Phase 4 | |
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Completed |
NCT04081272 -
Effect of G6PD Deficiency on Red Blood Cell Storage
|
||
Completed |
NCT04146246 -
Comparative Evaluation of the FINDER Instrument and FINDER G6PD Cartridge in Adults and Neonates
|
||
Recruiting |
NCT05026489 -
G6PD Deficiency in Infarction Patients in Shaanxi Province
|
||
Terminated |
NCT03337152 -
Assessing a Risk Model for G6PD Deficiency
|
Phase 4 | |
Completed |
NCT05753150 -
Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand
|
||
Completed |
NCT04010695 -
Validation of Diagnostics to Identify Glucose-6-phosphate Dehydrogenase Activity in the US
|
N/A | |
Completed |
NCT01931644 -
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
|
||
Active, not recruiting |
NCT03529396 -
Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients
|
Phase 2 | |
Recruiting |
NCT05874271 -
Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea
|
N/A | |
Recruiting |
NCT04088513 -
Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)
|
Phase 4 | |
Not yet recruiting |
NCT05571748 -
Oxidative Stress, Carbohydrate Metabolism Disorders and G6PD Deficiency
|
N/A | |
Not yet recruiting |
NCT02937376 -
Effects of N-acetyl Cystein (NAC) Supplementation in G6PD Deficient Individuals After Acute Exercise
|
Early Phase 1 | |
Completed |
NCT02937363 -
Effects of Alpha Lipoic Acid Supplementation in G6PD Deficient Individuals After Acute Exercise
|
N/A | |
Recruiting |
NCT05879224 -
Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia
|
N/A | |
Completed |
NCT04054661 -
Validation of a Diagnostic Test for Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency in Anti-coagulated Blood
|
N/A |